← Leaderboards
Juan Fernando Vera
Marker Therapeutics, Inc.
$7,624,284
Attributed
$9,295,816
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,067,614 · 5
FDA$1,228,202 · 1
By mechanism
R44$6,672,209 · 4
P50$1,395,405 · 1
R01$1,228,202 · 1
Top collaborators
- Laura S Angelo3 shared
- Brandon Smaglo2 shared
Most similar at Marker Therapeutics, Inc.
Same institution · by research overlap
- Laura S Angelo$997,257
- Brandon Smaglo$674,275
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorCancer CellMalignant NeoplasmsT Cell TherapyTumor AntigensT-LymphocyteSafetyTumor EscapeIn VivoCell TherapyAntigensCellsCytokineClinical ResearchNeoplastic CellInfusion ProceduresSignal TransductionClinical TrialsAntigen TargetingAntigen-Specific T CellsEnvironmentFutureDose
Grant awards (17)
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$1,348,474
R44 · FY2025 · CA · contact PI
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2025 · CA · contact PI
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665,000
R44 · FY2025 · CA · contact PI
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2025 · CA · contact PI
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$188,702
R01 · FY2025 · FD · contact PI
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2024 · CA · contact PI
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665,000
R44 · FY2024 · CA · contact PI
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2024 · CA · contact PI
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$650,671
R44 · FY2024 · CA · contact PI
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$519,750
R01 · FY2024 · FD · contact PI
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2023 · CA · contact PI
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$519,750
R01 · FY2022 · FD · contact PI
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc$293,263
P50 · FY2018 · CA · contact PI
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc$295,247
P50 · FY2017 · CA · contact PI
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc$275,666
P50 · FY2016 · CA · contact PI
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc$267,367
P50 · FY2015 · CA · contact PI
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc$263,862
P50 · FY2014 · CA · contact PI